

Faculty Name:	Cindy X. Cai, MD, PhD
Bio	Dr. Cai has been on faculty in the division of Gastroenterology and Hepatology at the VA Loma Linda Healthcare System and Loma Linda University since 2012. Her primary practice site is based at the VA Loma Linda where she implements the evidence-based medicine in the care of individual patients. She oversees the liver transplant program at the VA Loma Linda. Over the years, she has been involved in teaching fellows, residents and medical students both in general gastroenterology/hepatology and hospital medicine. Dr. Cai also has a strong interest in research where fellows, medical residents and students can participate. In her spare time, she enjoys family time, outdoor activities, and traveling
Clinical Focus	cirrhosis, HCC, liver transplant, NAFLD/ALD, viral hepatitis, metabolic liver disease
Research Interests	NAFLD, liver fibrosis/cirrhosis, HCC, transplant Molecular mechanisms for hepatic fibrogenesis/tumorigenesis Novel therapeutics for liver diseases
Appointments	
Academic Appointments	Associate Professor, Medicine, Loma Linda University Associate Clinical Professor, Medicine, University of California Riverside
Administrative Appointments	
Professional Education	
Medical School	Sun Yat-sun University of Medical Sciences
Residency	Saint Louis University, Internal Medicine
Fellowship	Saint Louis University, Gastroenterology
Professional Societies	
American Association for the Study of Liver Disease	
Selected Publications	
1.	Cindy X. Cai , Hema Buddha, Shobha Castelino-Prabhu, Zhiwei Zhang, Robert S. Britton, Bruce R. Bacon, Brent A. Neuschwander-Tetri. Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis. <i>Dig Dis Sci.</i> 2017 Feb; 62(4):968-78. PMID: 28194671
2.	Zhang Z and Cai CX . Kidney injury molecule-1 (KIM-1) enhances renal epithelial cell migration via ERK MAPK signaling pathway. <i>Mol Cell Biochem.</i> 2016 Apr; 15:1-8. PMID: 27084535
3.	Zhang Z, Maddukuri G, Jaipaul N, Cai CX . Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. <i>J Crit Care.</i> 2015 Oct;30(5):969-74. PMID: 26051980
4.	Cai CX , Maddukuri G, Jaipaul N, Zhang Z. A treat-to-target concept to guide the medical management of hepatorenal syndrome. <i>Dig Dis Sci.</i> 2015 May;60(5):1474-81. PMID: 25532500
5.	Maddukuri G , Cai CX , Munigala S , Mohammadi F , Zhang Z . Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study. <i>Dig Dis Sci.</i> 2014 Feb;59(2):471-81. PMID: 24146317